Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Natalizumab (Tysabri)

Natalizumab (Tysabri) This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: ajnr.A2226v1 31/9/1588 most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Google Scholar Articles by Selewski, D. T. Articles by Mukherji, S. K. PubMed PubMed Citation Articles by Selewski, D. T. Articles by Mukherji, S. K. Hotlight (NEW!) What's Hotlight? American Journal of Neuroradiology 31:1588-1590, October 2010 © 2010 American Society of Neuroradiology PHARMACOLOGY VIGNETTE Natalizumab (Tysabri) D.T. Selewski a , G.V. Shah b , B.M. Segal c , P.A. Rajdev d and S.K. Mukherji b a From the Department of Pediatrics, Division of Pediatric Nephrology (D.T.S.), University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, Michigan, Division of Neuroradiology b Department of Radiology (G.V.S., S.K.M.) and Multiple Sclerosis Center c Holtom-Garrett Program in Neuroimmunology, Department of Neurology (B.M.S.), University of Michigan Health System, Ann Arbor, Michigan d University of Michigan Medical School (P.A.R.), Ann Arbor, Michigan. Please address correspondence to David T. Selewski, MD, Department of Pediatrics, Division of Pediatric Nephrology, University of Michigan, C.S. Mott Children's Hospital, F6865, 1500 E. Medical Center Dr, SPC 5297, Ann Arbor, Michigan 48109-7789; e-mail: dselewsk@med.umich.edu SUMMARY: Natalizumab is a humanized IgG4 monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent. Abbreviations: FDA, US Food and Drug Administration • FLAIR, fluid-attenuated inversion recovery • FSE, fast spin-echo • IgG, immunoglobulin G • MAdCAM-1, mucosal adressin cell adhesion molecule • MS, multiple sclerosis • PML, progressive multifocal leukoencephalopathy • TOUCH, Tysabri Outreach Unified Commitment to Health • VCAM -1, vascular cell adhesion molecule-1 Home Subscribe Author Instructions Submit Online Search the AJNR Archives Feedback Help Copyright © 2010 by the American Society of Neuroradiology. Print ISSN: 0195-6108 Online ISSN: 1936-959X http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Neuroradiology American Journal of Neuroradiology

Natalizumab (Tysabri)

Download PDF
3 pages

Loading next page...
 
/lp/american-journal-of-neuroradiology/natalizumab-tysabri-2aBi09Hh1y
Publisher
American Journal of Neuroradiology
Copyright
Copyright © 2010 by the American Society of Neuroradiology.
ISSN
0195-6108
eISSN
1936-959X
DOI
10.3174/ajnr.A2226
Publisher site
See Article on Publisher Site

Abstract

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: ajnr.A2226v1 31/9/1588 most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Google Scholar Articles by Selewski, D. T. Articles by Mukherji, S. K. PubMed PubMed Citation Articles by Selewski, D. T. Articles by Mukherji, S. K. Hotlight (NEW!) What's Hotlight? American Journal of Neuroradiology 31:1588-1590, October 2010 © 2010 American Society of Neuroradiology PHARMACOLOGY VIGNETTE Natalizumab (Tysabri) D.T. Selewski a , G.V. Shah b , B.M. Segal c , P.A. Rajdev d and S.K. Mukherji b a From the Department of Pediatrics, Division of Pediatric Nephrology (D.T.S.), University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, Michigan, Division of Neuroradiology b Department of Radiology (G.V.S., S.K.M.) and Multiple Sclerosis Center c Holtom-Garrett Program in Neuroimmunology, Department of Neurology (B.M.S.), University of Michigan Health System, Ann Arbor, Michigan d University of Michigan Medical School (P.A.R.), Ann Arbor, Michigan. Please address correspondence to David T. Selewski, MD, Department of Pediatrics, Division of Pediatric Nephrology, University of Michigan, C.S. Mott Children's Hospital, F6865, 1500 E. Medical Center Dr, SPC 5297, Ann Arbor, Michigan 48109-7789; e-mail: dselewsk@med.umich.edu SUMMARY: Natalizumab is a humanized IgG4 monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent. Abbreviations: FDA, US Food and Drug Administration • FLAIR, fluid-attenuated inversion recovery • FSE, fast spin-echo • IgG, immunoglobulin G • MAdCAM-1, mucosal adressin cell adhesion molecule • MS, multiple sclerosis • PML, progressive multifocal leukoencephalopathy • TOUCH, Tysabri Outreach Unified Commitment to Health • VCAM -1, vascular cell adhesion molecule-1 Home Subscribe Author Instructions Submit Online Search the AJNR Archives Feedback Help Copyright © 2010 by the American Society of Neuroradiology. Print ISSN: 0195-6108 Online ISSN: 1936-959X

Journal

American Journal of Neuroradiology – American Journal of Neuroradiology

Published: Oct 1, 2010

There are no references for this article.